Acorda Therapeutics Announces Filing of Patent Extension Applications for AMPYRA™ (dalfampridine)

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office (USPTO).